During Q3 2018 the big money sentiment increased to 1.41. That’s change of 0.48, from 2018Q2’s 0.93. 12 investors sold all, 52 reduced holdings as Pacira Pharmaceuticals, Inc. ratio improved. 43 rose holdings while 47 funds acquired holdings. Funds hold 39.60 million shares thus 2.00% less from 2018Q2’s 40.41 million shares.
Polar Capital Llp stated it has 0.12% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). State Street Corp invested in 0% or 987,396 shs. Rhumbline Advisers holds 37,391 shs or 0% of its capital. Moreover, Consonance Capital Mngmt Limited Partnership has 9.66% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Jpmorgan Chase & reported 0% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Canada Pension Plan Board holds 0.02% or 232,986 shs. Partners Limited Liability Com holds 0.14% of its capital in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 69,706 shs. Cubist Systematic Strategies Ltd Company holds 2,998 shs. Healthcor L P holds 1.95 million shs. Td Asset Management Inc stated it has 22,500 shs or 0% of all its holdings. Moreover, Price T Rowe Associate Md has 0.01% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Virtu Fincl Limited Com has invested 0% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Tocqueville Asset Limited Partnership accumulated 10,000 shs or 0.01% of the stock. Chicago Equity Partners Llc has 93,640 shs for 0.14% of their capital. Malaga Cove Cap Lc has 23,646 shs.

Pacira Pharmaceuticals, Inc. had 7 selling transactions and 2 buys since September 24, 2018. This’s net activity of $7.44 million. Another trade for 15,000 shs valued at $710,801 was made by STACK DAVID M on Thursday, November 15. $46,605 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was sold by Wicki Andreas. $54,350 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was sold by Riker Lauren Bullaro.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Ratings Coverage

Total analysts of 8 have positions in Pacira Pharmaceuticals (NASDAQ:PCRX) as follows: 2 rated it a “Buy”, 2 with “Sell” and 4 with “Hold”. The positive are 25%. Since September 14, 2018 according to StockzIntelligence Inc Pacira Pharmaceuticals has 11 analyst reports. In Friday, February 1 report Mizuho downgraded the stock to “Underperform” rating. On Thursday, February 28 the rating was maintained by Mizuho with “Sell”. In Friday, March 1 report H.C. Wainwright maintained it with “Buy” rating and $60 target. On Tuesday, October 2 Canaccord Genuity maintained the shares of PCRX in report with “Hold” rating. The company rating was maintained by BMO Capital Markets on Friday, November 2. On Friday, November 2 JP Morgan maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) with “Neutral” rating. On Friday, March 1 the stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) earned “Hold” rating by BMO Capital Markets. On Friday, November 2 the firm earned “Market Outperform” rating by JMP Securities. On Wednesday, October 10 the firm has “Neutral” rating by Bank of America given. Listed here are Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) PTs and latest ratings.

28/02/2019 Broker: Mizuho Rating: Sell New Target: $30 Maintain
01/03/2019 Broker: Cowen & Co Rating: Hold Maintain
01/03/2019 Broker: BMO Capital Markets Rating: Hold New Target: $44 Maintain
01/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $60 Maintain
01/02/2019 Broker: Mizuho Old Rating: Neutral New Rating: Underperform Downgrade
02/11/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $45 New Target: $50 Maintain
02/11/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $40 New Target: $47 Maintain
02/11/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $56 New Target: $63 Maintain
10/10/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $46 New Target: $48 Maintain
02/10/2018 Broker: Canaccord Genuity Old Rating: Hold New Rating: Hold Old Target: $45 New Target: $49 Maintain

PCRX is reaching $42.17 during the last trading session, after increased 2.40%.Pacira Pharmaceuticals, Inc. has 1.34M shares volume, 121.10% up from normal. PCRX is uptrending and has moved 6.95% since March 3, 2018. The stock outperformed the S&P 500 by 6.95%.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States.The firm is worth $1.73 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.Last it reported negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

For more Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) news brought out briefly go to: Seekingalpha.com, Nasdaq.com, , Nasdaq.com or Seekingalpha.com. The titles are as follows: “Pacira Pharmaceuticals (PCRX) Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” brought out on August 02, 2018, “Implied Volatility Surging for Pacira Pharmaceuticals (PCRX) Stock Options – Nasdaq” on September 20, 2018, “The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs – Yahoo Finance” with a publish date: February 22, 2019, “Why Is Pacira (PCRX) Down 7.3% Since Last Earnings Report? – Nasdaq” and the last “Pacira’s Exparel shows treatment benefit in C-section patients – Seeking Alpha” with publication date: December 12, 2018.